Mammary Cell News Volume 9.45 | Nov 16 2017

TOP STORY

Neratinib after Trastuzumab-Based Adjuvant Therapy in HER2-Positive Breast Cancer (ExteNET): 5-Year Analysis of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

Researchers report updated efficacy outcomes from a protocol-defined five-year follow-up sensitivity analysis and long-term toxicity findings. [Lancet Oncol] Abstract | Press Release

(Ranked by impact factor of the journal)

JAK2-Binding Long Noncoding RNA Promotes Breast Cancer Brain Metastasis

LncRNA associated with breast cancer brain metastases (Lnc-BM) increased JAK2 kinase activity to mediate oncostatin M– and IL-6–triggered STAT3 phosphorylation. In breast cancer cells, Lnc-BM promoted STAT3-dependent expression of ICAM1 and CCL2, which mediated vascular co-option and recruitment of macrophages in the brain, respectively. [J Clin Invest] Full Article

Hit-and-Run Epigenetic Editing Prevents Senescence Entry in Primary Breast Cells from Healthy Donors

Scientists showed simultaneous de novo DNA methylation of genes commonly methylated in cancer, CDKN2A, RASSF1, HIC1 and PTEN in primary breast cells isolated from healthy human breast tissue. [Nat Commun] Full Article

Pyk2 and FAK Differentially Regulate Invadopodia Formation and Function in Breast Cancer Cells

The authors identify proline-rich tyrosine kinase 2 (Pyk2) as a unique mediator of invadopodium formation and function and also provide a novel insight into the mechanisms by which Pyk2 mediates tumor cell invasion. [J Cell Biol] Abstract

MTA1 Is a Novel Regulator of Autophagy That Induces Tamoxifen Resistance in Breast Cancer Cells

Investigators demonstrated that metastasis-associated 1 (MTA1) induces AMPK activation and subsequent autophagy that could contribute to tamoxifen resistance in breast cancer. [Autophagy] Abstract

Raptor Localization Predicts Prognosis and Tamoxifen Response in Estrogen Receptor-Positive Breast Cancer

In vitro, the MCF7 breast cancer cell line and tamoxifen-resistant MCF7 cells were studied to track the raptor signaling changes upon resistance, and raptor localization in ERα-positive cell lines was compared with that in ERα-negative cell lines. [Breast Cancer Res Treat] Full Article

MiR-361-5p Inhibits Glycolytic Metabolism, Proliferation and Invasion of Breast Cancer by Targeting FGFR1 and MMP-1

Scientists report that miR-361-5p was down-regulated in breast cancer tissue compared with normal breast tissue and the expression of miR-361-5p was positively associated with prognosis in breast cancer patients. Functional studies showed that overexpression of miR-361-5p suppressed the proliferation, invasion and metastasis of breast cancer cells both in vivo and in vitro. [J Exp Clin Cancer Res] Full Article

MicroRNA-7-5p Mediates the Signaling of Hepatocyte Growth Factor to Suppress Oncogenes in the MCF-10A Mammary Epithelial Cell

Researchers performed a genome-wide expression analysis in miR-7-transfected MCF-10A breast cell line to explore the upstream regulators of miR-7. MiR-7 was upregulated in MCF-10A cells by hepatocyte growth factor (HGF), and subsequently downregulated upon treatment with siRNA against HGF. [Sci Rep] Full Article

miR-17-5p Suppresses Cell Proliferation and Invasion by Targeting ETV1 in Triple-Negative Breast Cancer

The authors report that ETS variant 1 (ETV1) is a significant oncogene in triple-negative breast cancer (TNBC) tumourigenesis. Consequently, investigating the critical regulatory microRNAs of ETV1 may be beneficial for TNBC targeted therapy. [BMC Cancer] Full Article

Pterostilbene Down-Regulates hTERT at Physiological Concentrations in Breast Cancer Cells: Potentially through the Inhibition of cMyc

Investigators found that pterostilbene inhibits the cellular proliferation of MCF-7 and MDA-MB-231 breast cancer cells in both a time- and dose-dependent manner, without significant toxicity to the MCF10A control cells. cMyc, a proposed target of the pterostilbene-mediated inhibition of human telomerase reverse transcriptase (hTERT), was down-regulated both transcriptionally and posttranscriptionally after treatment. [J Cell Biochem] Abstract

Implications of Aging and the Endoplasmic Reticulum Unfolded Protein Response on the Molecular Modality of Breast Cancer

The authors present a collection of data that can delineate the missing links of molecular signatures between aging and breast cancer. [Exp Mol Med] Full Article

Triple-Negative Breast Cancer, Stem Cells, and African Ancestry

Researchers summarize the existing literature regarding triple-negative breast cancers and stem cells as they pertain to the breast cancer burden of African ancestry populations. Additional research related to variation in somatic tumor genomics between African American and Caucasian American is also summarized. [Am J Pathol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Syros to Present New Preclinical Data on SY-1365 and on Identification of Potential Drug Targets in Triple Negative Breast Cancer

Syros Pharmaceuticals announced that the Company will present new preclinical data identifying potential biomarkers predictive of response to SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor currently in a Phase I clinical trial in advanced solid tumors [Press release from Syros Pharmaceuticals, Inc. discussing research to be presented at the San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release

Novartis Presents New Data at SABCS Across Broad Range of Breast Cancer Patient Populations, Combination Treatments and Lines of Therapy

Novartis will present data across its breast cancer portfolio and pipeline in a broad range of patient populations, treatment combinations and pathways. [Press release from Novartis discussing research presented at the 40^th annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release

FASLODEX^® (Fulvestrant) Receives FDA Approval for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib

AstraZeneca announced that the FDA has approved a new indication for FASLODEX^®, expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in women with disease progression after endocrine therapy. [AstraZeneca] Press Release

Breast Cancer Patients to Have Routine Access to Two Life Extending Drugs after New Deal, Say NICE in Draft Guidance

The National Institute for Health and Care Excellence (NICE) has recommended palbociclib and ribociclib for routine funding after the companies lowered the prices and gave more evidence for their effectiveness. [National Institute for Health and Care Excellence] Press Release

African Scientists Get Their Own Open-Access Publishing Platform

Africa’s academy of science has announced that it will launch an open-access publishing platform — the first of its kind aimed exclusively at scientists on the continent. [Nature News] Editorial

Graduate Students Face Alarming Tax Hike

The last thing that graduate students need is a tax hike. But that is what many would face under a clause in the federal-tax-reform bill passed by the US House of Representatives. It will need to be reconciled with the Senate’s tax-reform bill (which retains many existing student tax benefits), and signed by the president. [Nature News] Editorial

NEW Lorne Cancer Conference 2018
February 8-10, 2018
Lorne, Australia

NEW 7^th International Symposium on Hereditary Breast and Ovarian Cancer
May 8-11, 2018
Montreal, Quebec, Canada

Visit our events page to see a complete list of events in the community.

NEW Cancer Bioinformatician – Breast Cancer Research (Institute of Cancer Research)

NEW Postdoctoral Research Scientist/Fellow – Epigenetic Gene Regulation in Breast Cancer (Columbia University Medical Center)

Postdoctoral Research Scientist/Fellow – Breast Cancer (Columbia University)

Postdoctoral Training Fellow – Breast Cancer Organoids (Institute of Cancer Research)

Executive Director – Breast Cancer Research (Indiana University School of Medicine)

Cancer Bioinformatician – Breast Cancer Research (Institute of Cancer Research)

PhD Studentships – Cancer Research (University of Cambridge)

Postdoctoral Positions – Breast Cancer (Northwestern University- Feinberg School of Medicine)

Physician Scientist – Translational Research in Breast Cancers (University of New Mexico)

Postdoctoral Fellow – Translational Research in Breast Cancer (University of Texas Southwestern Medical Center)

Postdoctoral Positions – Interdisciplinary Translational Research (University of Texas Health Science Center at San Antonio)

Postdoctoral Fellowship – Breast Cancer Research (Geisel School of Medicine at Dartmouth)

Assistant Professor – Cancer Biology (Perelman School of Medicine)

Assistant Professor – Cancer Research (University of Minnesota)

Postdoctoral Position – Transcriptomics and Cancer Epigenetics (Universität Basel)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.